Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study

Affiliations

¹ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
² Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
³ Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
⁴ The Institute of Primary Health Care, University of Bern, Bern, Switzerland.
⁵ Global Development, Amgen, Thousand Oaks, CA, USA.
⁶ David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
⁷ Flourish Research, Boca Raton, FL, USA.
⁸ Crossroads Clinical Research, Mooresville, NC.
⁹ Department of Medicine, Université de Montréal, Montréal, Canada.
¹⁰ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, 7th Floor, Boston, MA 02115, USA.

Gurleen Kaur et al. Eur Heart J. 2025.

. 2025 Mar 24;46(12):1162-1164.

doi: 10.1093/eurheartj/ehae781.

¹ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
² Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
³ Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
⁴ The Institute of Primary Health Care, University of Bern, Bern, Switzerland.
⁵ Global Development, Amgen, Thousand Oaks, CA, USA.
⁶ David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
⁷ Flourish Research, Boca Raton, FL, USA.
⁸ Crossroads Clinical Research, Mooresville, NC.
⁹ Department of Medicine, Université de Montréal, Montréal, Canada.
¹⁰ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Rd, 7th Floor, Boston, MA 02115, USA.